Navigation Links
AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
Date:1/11/2011

WILMINGTON, Del. and NASHVILLE, Tenn., Jan. 11, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) and Sarah Cannon Research Institute (SCRI), an international leader in advancing therapies for cancer patients through clinical research, today announced that SCRI will lead the clinical development of a novel targeted oncology compound from AstraZeneca.

Cancer is a major cause of mortality globally; accounting for 7.4 million (or 13%) of all deaths in 2004. The World Health Organization estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015, driving the critical need for novel therapies to reach patients quickly and efficiently.

Under the agreement, SCRI will collaborate with AstraZeneca to provide clinical program development expertise, clinical program design, medical oversight and trial management. The first clinical trial to be conducted under the agreement was initiated in November 2010 with the first patient enrollment into that clinical trial on November 23, 2010.  

Potential benefits to be derived from this unique collaboration include enhanced strategic clinical development in pursuit of new and more effective cancer therapies, flexibility in program design and implementation, innovation via realizing efficiencies across the collaboration, leveraging the strengths of the innovative collaboration, and rapid patient enrollment to clinical trials through the access of a large network of cancer patients.  

Andrew Hughes, Vice President, Oncology Clinical Innovative Medicines, said: "AstraZeneca has a long history of discovering and developing cancer therapeutics that have made a real difference to cancer patients. For many years we have enjoyed an excellent working relationship with SCRI and this is an exciting next step in our relationship that continues to foster collaboration and innovation in advancing the field of cancer research. The collaboration is unique because SCRI will assist AstraZeneca with both the design and delivery of a new agent from its first studies in cancer patients to proof of concept at the conclusion of Phase II and we are delighted to be working with SCRI in this innovative way."

"We are pleased to engage in this strategic collaboration, bringing together some of the world's strongest physicians and scientists to optimize the development of new therapies for patients with cancer," said Dee Anna Smith, CEO of SCRI.  "We look forward to providing AstraZeneca with exceptional drug development services while leveraging an industry-leading opportunity to explore a new way for pharmaceutical drug development companies to collaborate."

"This type of strategic partnership is an exciting opportunity to demonstrate how clinical scientists and industry can collaborate for the greater good of patients. I believe the structure of the relationship will enable us to both adapt and move quickly from one study to the next as the clinical program progresses," said Howard A. "Skip" Burris III, M.D., SCRI chief medical officer and director of drug development. 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit: www.astrazeneca.com

SCRI Company

SCRI is a strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs in the nation, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 450 physicians in 24 states. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites across the country. For more information, please visit www.sarahcannonresearch.com.  

Contacts:


AstraZeneca

Andrea Conners

Office: 302-885-7652

Mobile: 610-620-5675

Andrea.conners@astrazeneca.com


Sarah Cannon Research Institute

Michele Toungette

Office: 615-524-4051

Mobile: 615-812-4273

Michele.Toungette@scresearch.net





'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
2. Rigel Earns Milestone Payments From AstraZeneca
3. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
4. AstraZeneca Outlines Principles for Product-Related Online Communications
5. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
6. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
7. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
8. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
9. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary Medicine ... experienced veterinary clients have treated over 100 of their own patients with the VetStem ... the highest level of care for their patients. , The veterinarians are Dr ...
(Date:5/20/2016)... , ... May 20, 2016 , ... The recent recall ... as reported by Food Safety News on May 12, 2016(1), demonstrates the need for ... Olsen, CEO of Baltimore-based biotech firm, PathSensors, Inc. , PathSensor’s latest ...
(Date:5/19/2016)... 2016 There is no saying ... the relentless pressures in pricing and lack in consumer ... circle though - numerous opportunities are up for grabs ... ActiveWallSt.com,s presents four names in this sector: Portola Pharmaceuticals ... (NASDAQ: VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... - I dati saranno presentati ... 52 ° Congresso della Società ... - Le conclusioni dello studio indicano un tasso di ... cui il 90% presenta una d urata della risposta ... settantadue per cento dei pazienti ha riscontrato un beneficio clinico. ...
Breaking Biology Technology:
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/10/2016)... India , March 10, 2016 ... a new market research report "Identity and Access Management ... & Audit, Compliance, and Governance), by Organization Size, by ... to 2020", published by MarketsandMarkets, The market is estimated ... USD 12.78 Billion by 2020, at a Compound Annual ...
(Date:3/9/2016)... 9, 2016 This BCC Research report provides ... the RNA Sequencing (RNA Seq) market for the years ... tools and reagents, data analysis, and services. ... the RNA-Sequencing market such as RNA-Sequencing tools and reagents, ... factors affecting each segment and forecast their market growth, ...
Breaking Biology News(10 mins):